{"name":"USWM CT, LLC","slug":"uswm-ct-llc","ticker":"","exchange":"","domain":"uswmctllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADP adoptive cell therapy","genericName":"ADP adoptive cell therapy","slug":"adp-adoptive-cell-therapy","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADP adoptive cell therapy","genericName":"ADP adoptive cell therapy","slug":"adp-adoptive-cell-therapy","phase":"phase_1","mechanism":"Adoptive cell therapy that transfers immune cells to patients to enhance anti-tumor or anti-disease immune responses.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTDcwc0YzQ0o1SDBocXhzbUFKMDdKQktrRmQyUXJ3d3RGV2Z4VURBbW02Z2ZhNlQ1dzRsXy1vTkJrWHZYMHBxWnljS21pVWdUQ0paT2dPQ19vQThKN1dZQnJLQXFRYlQ5OEhCalJKbWFyVkdLWmh2N0p3YUhhOUhZVHhBUHMwaFlJcWhHcnBGbDdHUmUtQWtrblEtRFM?oc=5","date":"2026-03-06","type":"trial","source":"openPR.com","summary":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma - openPR.com","headline":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNeUg5RjV0OTBXMVBNWERuNVpGNnZxMDAzekxadUZST29sbnJoTFRMMHM4V3A3Q2x4ckNfU1pjbTM5U09qNTRlaWRjOEpzUnBqaWhKQkNiMXhYVVQwN3VELWJURlo5YmxSQncxeXIwY0xyVFF1V3hLOE1GTTZ4ZWNGS0YzQmFndHFTQURUeWJOUFhMUEN6bmVkQUM3VWlDQQ?oc=5","date":"2025-07-28","type":"pipeline","source":"Fierce Biotech","summary":"Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs - Fierce Biotech","headline":"Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}